Literature DB >> 7689456

Quinolone mode of action--new aspects.

D C Hooper1.   

Abstract

The interactions of quinolones with the complex of DNA gyrase and DNA have been elucidated by the sequencing of additional mutant gyrA and gyrB genes that produce altered quinolone susceptibility. Strong patterns have emerged in Escherichia coli in which amino acids between positions 67 and 106 of the gyrase A subunit (GyrA) and at positions 426 and 447 of the gyrase B subunit (GyrB) have been consistently identified as important for quinolone action. The susceptibility patterns and changes in amino acids 426 and 447 in mutant resistant GyrB proteins suggest direct electrostatic interactions with quinolones at these positions. The small size and the polar nature of the serine at position 83 of the E. coli GyrA protein are particularly important for determining enzyme sensitivity and bacterial susceptibility to quinolones. Norfloxacin and ciprofloxacin bind most stably to a complex of DNA gyrase and DNA rather than to either component alone, and reduction of norfloxacin binding to complexes containing resistant GyrA proteins confirms the biological relevance of this direct measure of quinolone interaction with the gyrase-DNA complex. Although recent crystallographic studies have expanded and refine information about gyrase structure at the atomic level, direct determination of the sites of quinolone binding within the gyrase-DNA complex awaits further studies. Although quinolones have little activity against E. coli topoisomerases I and III, topoisomerase IV, a recently described enzyme thought to be involved in chromosome segregation into daughter cells, has homology with GyrA and GyrB, particularly in regions important for quinolone action, and is inhibited by some quinolones in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689456     DOI: 10.2165/00003495-199300453-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  53 in total

1.  Purification and characterization of DNA topoisomerase IV in Escherichia coli.

Authors:  J Kato; H Suzuki; H Ikeda
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

2.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

Authors:  L L Shen; W E Kohlbrenner; D Weigl; J Baranowski
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

3.  Role of autolysins in the activities of imipenem and CGP 31608, a novel penem, against slowly growing bacteria.

Authors:  R M Cozens; Z Markiewicz; E Tuomanen
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.

Authors:  P Hussy; G Maass; B Tümmler; F Grosse; U Schomburg
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

5.  Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase.

Authors:  C S Lewin; B M Howard; J T Smith
Journal:  J Med Microbiol       Date:  1991-01       Impact factor: 2.472

Review 6.  DNA gyrase: structure and function.

Authors:  R J Reece; A Maxwell
Journal:  Crit Rev Biochem Mol Biol       Date:  1991       Impact factor: 8.250

7.  Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

Authors:  H Yoshida; T Kojima; J Yamagishi; S Nakamura
Journal:  Mol Gen Genet       Date:  1988-01

8.  Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282.

Authors:  W E Kohlbrenner; N Wideburg; D Weigl; A Saldivar; D T Chu
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

9.  Effects of quinolones on nucleoid segregation in Escherichia coli.

Authors:  N H Georgopapadakou; A Bertasso
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

10.  Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents.

Authors:  J S Wolfson; D C Hooper; G L McHugh; M A Bozza; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more
  17 in total

1.  Induction of DnaK and GroEL heat shock proteins by fluoroquinolones in Escherichia coli.

Authors:  T Mizushima; M Matsuo; K Sekimizu
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

2.  In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites.

Authors:  H Gmünder; K Kuratli; W Keck
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

3.  Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis.

Authors:  H Gmuender; K Kuratli; C P Gray; W Keck; S Evers
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

4.  Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.

Authors:  H Wang; J L Dzink-Fox; M Chen; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 5.  The uptake mechanisms of inflammation- and infection-localizing agents.

Authors:  W J Oyen; O C Boerman; C J van der Laken; R A Claessens; J W van der Meer; F H Corstens
Journal:  Eur J Nucl Med       Date:  1996-04

Review 6.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 7.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

8.  Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Authors:  Michelle Sabourin; John L Nitiss; Karin C Nitiss; Kazuo Tatebayashi; Hideo Ikeda; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

Review 9.  Quinolone mode of action.

Authors:  D C Hooper
Journal:  Drugs       Date:  1995       Impact factor: 9.546

10.  CP-115,953 stimulates cytokine production by lymphocytes.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.